MCPyV TAg-specific polyclonal autologous CD8-positive T-cell immunotherapy (Fred Hutchinson Cancer Research Center)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameMCPyV TAg-specific polyclonal autologous CD8-positive T-cell immunotherapy (Fred Hutchinson Cancer Research Center)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Virus-specific T Cell therapy

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsCarcinoma, Merkel Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesFred Hutchinson Cancer Research Center National Cancer Institute

China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer Institute Fred Hutchinson Cancer Research Center

Inactive CompaniesN/A

Active IndicationsCarcinoma, Merkel Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A